Drugs / GSK2302032A
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01159964 | Jul 2010 → Oct 2011 | non-small cell lung carcinoma | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT01853878 | Jun 2013 → Aug 2016 | non-small cell lung carcinoma | GlaxoSmithKline | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2302032A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01159964 ↗ |
| Modality | Vaccine | “Evaluation of a New Anti-cancer Vaccine for Patients With Non-small Cell Lung Cancer” NCT01159964 ↗ |
| Route | Intramuscular | “Intramuscular administration” NCT01159964 ↗ |